BriaCell Therapeutics (NASDAQ:BCTX) PT Lowered to $15.00 at HC Wainwright

BriaCell Therapeutics (NASDAQ:BCTX) had its price objective reduced by investment analysts at HC Wainwright from $18.00 to $15.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock.

BriaCell Therapeutics Price Performance

Shares of NASDAQ:BCTX opened at $0.52 on Thursday. The stock’s 50-day moving average is $0.72 and its 200 day moving average is $1.56. The company has a market cap of $9.57 million, a PE ratio of -0.42 and a beta of 1.31. BriaCell Therapeutics has a 1 year low of $0.46 and a 1 year high of $6.36.

Hedge Funds Weigh In On BriaCell Therapeutics

An institutional investor recently raised its position in BriaCell Therapeutics stock. Onyx Bridge Wealth Group LLC grew its stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 66.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 50,000 shares of the company’s stock after purchasing an additional 20,000 shares during the quarter. Onyx Bridge Wealth Group LLC owned about 0.31% of BriaCell Therapeutics worth $143,000 at the end of the most recent quarter. 15.42% of the stock is currently owned by institutional investors and hedge funds.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.